Treatable Meningeal Involvement in Waldenstrom's Macroglobulinemia

Brief Reports1 September 1984Treatable Meningeal Involvement in Waldenstrom's MacroglobulinemiaJAMES J. TORREY, M.D., SURESH B. KATAKKAR, M.D.JAMES J. TORREY, M.D.Search for more papers by this author, SURESH B. KATAKKAR, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-101-3-345 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCENTRAL NERVOUS SYSTEM infiltration in Waldenstrom's macroglobulinemia is uncommon and difficult to diagnose in living patients. We report the case of a patient in whom we were able to detect meningeal involvement by biopsy and subsequently successfully treat the condition.In 1977, a 69-year-old woman with progressive weakness was found to have blood and bone marrow features of Waldenstrom's macroglobulinemia. She was treated with various regimens, including chlorambucil, cyclophosphamide, vincristine, bleomycin, and prednisone, over a 6-year period, with responses of 4 months to 2 years. Her serum IgM (kappa) level had decreased from 7360 IU (normal range, 69 to 322...References1. RATCHESONOMMAYA RA. Experience with the subcutaneous cerebrospinal-fluid reservoir: preliminary report of 60 cases. N Engl J Med. 1968;279:1025-31. CrossrefMedlineGoogle Scholar2. BINGNEEL JA. TWO cases of hyperglobulinemia with affection of the central nervous system on a toxi-infectious basis. Acta Med Scand. 1936;88:492-506. CrossrefGoogle Scholar3. WALDENSTROM J. Incipient myelomatosis or "essential" hyperglobulinemia with fibrinogenopenia—a new syndrome? Acta Med Scand. 1944;117:216-47. CrossrefGoogle Scholar4. LOGOTHETISSILVERSTEINCOE JPJ. Neurologic aspects of Waldenstrom's macroglobulinemia. Arch Neurol. 1960;3:564-73. CrossrefMedlineGoogle Scholar5. EDGARDUTCHER RT. Histopathology of the Bing-Neel syndrome. Neurology (NY). 1961;11:239-45. CrossrefMedlineGoogle Scholar6. KYLEGREIPP RP. The laboratory investigation of monoclonal gammopathies. Mayo Clin Proc. 1978;53:719-39. MedlineGoogle Scholar7. DE VITADENHAMDAVIDSONOLIVERIO VCJV. The physiologic disposition of carcinostatic l,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) in man and animals. Clin Pharmacol Ther. 1967;8:566-77. CrossrefMedlineGoogle Scholar8. CASE D. Combination chemotherapy (M-2) protocol (BCNU, cyclophosphamide, vincristine, melphalan, prednisone) for Waldenstrom's macroglobulinemia: preliminary report. Blood. 1982;59:934-7. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: St. Mary's Hospital Tucson, Arizona. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byBing–Neel syndrome: Two unexpected cases and a review of the literatureSuccessful Treatment of Bing-Neel Syndrome Using Intrathecal Chemotherapy and Systemic Combination Chemotherapy Followed by BEAM Auto-Transplant: A Case Report and Review of LiteratureOrbital Involvement in Bing-Neel SyndromeBing–Neel syndrome: an illustrative case and a comprehensive review of the published literatureBing-Neel Syndrome: A Case Report and Systematic Review of Clinical Manifestations, Diagnosis, and Treatment OptionsTherapeutic Experience of Bing-Neel Syndrome Associated with Waldenstrom's MacroglobulinemiaWaldenström’s Macroglobulinemia: Clinical Features, Complications, and ManagementWaldenström's Macroglobulinemia: Long-Term Results with the M-2 ProtocolPlasma Cell Dyscrasias: Definition and Diagnostic EvaluationReferences 1 September 1984Volume 101, Issue 3Page: 345-347KeywordsBiopsyBloodBone marrowCentral nervous systemCyclophosphamide Issue Published: 1 September 1984 PDF downloadLoading ...